What is Cullgen?
Founded in 2018 and based in San Diego, California, Cullgen is a privately held biopharmaceutical firm dedicated to pioneering first-in-class new chemical entities (NCEs) for diseases with limited treatment options. The company's core innovation lies in its ubiquitin-mediated, small molecule-induced target elimination technology, a platform leveraging recent breakthroughs in protein degradation science. This technology aims to create highly targeted therapies by selectively degrading disease-causing proteins.
How much funding has Cullgen raised?
Cullgen has raised a total of $106M across 3 funding rounds:
Series A
$16M
Series B
$50M
Series C
$40M
Series A (2019): $16M, investors not publicly disclosed
Series B (2021): $50M led by South China Venture Capital, Height Capital Management, 3E Bioventures Capital, MSA Capital, and Octagon Capital
Series C (2023): $40M supported by GNI Group, AstraZeneca, and Wuxi Venture Capital Group
Key Investors in Cullgen
GNI Group
GNI Group is a global healthcare company based in Japan, focused on drug discovery, manufacturing, and sales, aiming to address unmet medical needs worldwide through its unique drug discovery platform.
AstraZeneca
AstraZeneca is a global biopharmaceutical company concentrating on the discovery, development, and commercialization of prescription medicines in Oncology and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Wuxi Venture Capital Group
Wuxi Venture Capital Group, established in 2000, is an early equity and venture capital institution in Wuxi, primarily funded by government resources, focusing on providing financing support for small and medium-sized technology enterprises and government projects.
What's next for Cullgen?
The substantial enterprise-level backing Cullgen has received, particularly the recent major strategic investment, positions the company for significant growth and pipeline expansion. This capital infusion is anticipated to fuel further research and development, clinical trial progression, and the scaling of its operational capabilities. Cullgen's focus on a novel mechanism of action in drug discovery suggests a strategic move towards addressing complex therapeutic challenges, potentially leading to the development of groundbreaking treatments.
See full Cullgen company page
